CAMLG

Last update 08 May 2025

Basic Info

Synonyms

calcium modulating ligand, Calcium signal-modulating cyclophilin ligand, CAML

+ [3]

Introduction

Required for the post-translational delivery of tail-anchored (TA) proteins to the endoplasmic reticulum (PubMed:23041287, PubMed:24392163, PubMed:27226539). Together with GET1/WRB, acts as a membrane receptor for soluble GET3/TRC40, which recognizes and selectively binds the transmembrane domain of TA proteins in the cytosol (PubMed:23041287, PubMed:24392163, PubMed:27226539). Required for the stability of GET1 (PubMed:32187542). Stimulates calcium signaling in T cells through its involvement in elevation of intracellular calcium (PubMed:7522304). Essential for the survival of peripheral follicular B cells (By similarity).

100 Clinical Results associated with CAMLG

100 Translational Medicine associated with CAMLG

0 Patents (Medical) associated with CAMLG

104

Literatures (Medical) associated with CAMLG

01 May 2025·Molecular Neurobiology

Characterizing Genetic-Predisposed Proteins Involving Insomnia by Integrating Genome-Wide Association Study Summary Statistics

Article

Author: Long, Jiang ; Tang, Xiangdong ; Gu, Xiaojing ; Dou, Meng

Large case-control genome-wide association studies (GWASs) have detected loci associated with insomnia, but how these risk loci confer disease risk remains largely unknown. By integrating brain protein quantitative trait loci (pQTL) (N_pQTL1 = 376, N_pQTL2 = 152) and expression QTL (eQTL) (N = 452) datasets, with the latest insomnia GWAS summary statistics (N_case = 109,548, N_Controls = 277440), we conducted proteome/transcriptome-wide association study (PWAS/TWAS) and Mendelian randomization (MR) analysis, aiming to identify causal proteins involving in the pathogenesis of insomnia. We also explored the bi-directional causality between insomnia and several common diseases. As a result, the altered protein level of 28 genes in the brain was associated with the risk of insomnia in the discovery stage of PWAS, of which 18 genes' associations were replicated in the confirmatory stage of PWAS. Among them, four proteins (2-aminoethanethiol dioxygenase (ADO), calcium-modulating cyclophilin ligand (CAMLG), islet cell autoantigen 1 like (ICA1L) and latexin (LXN)) were found to be the most likely causal genes for insomnia with validations from TWAS, MR, and colocalization results. Specifically, the higher protein level of ADO, CALMG, and ICA1L was causally associated with a lower risk of insomnia. In comparison, the higher protein level of LXN was causally associated with an increased risk for insomnia. Moreover, genetically predicted insomnia was causally associated with an increased risk of developing cardiovascular diseases and depression. In conclusion, our study identified ADO, CAMLG, ICA1L, and LXN as potentially causal proteins in the pathogenesis of insomnia. This could provide insights into further mechanistic studies and therapeutic development for insomnia.

06 Nov 2024·Journal of Agricultural and Food Chemistry

Membrane Interactions of GET1 and GET2 Facilitate Fiber Cell Initiation through the Guided Entry of the TA Protein Pathway in Cotton

Article

Author: Wang, Zhi ; Pei, Yanfei ; Gan, Lei ; Liu, Yang ; Liu, Ji ; Zhang, Tianen ; Miao, Pengfei ; Pei, Yayue ; Zou, Xianyan ; Li, Fuguang ; Yang, Lu ; Wei, Zhenzhen ; Yang, Zuoren ; Peng, Jun

The guided entry of TA proteins (GET) pathway, which is responsible for the post-translational targeting and insertion of the tail-anchored (TA) protein into the endoplasmic reticulum (ER), plays an important role in physiological processes such as protein sorting, vesicle trafficking, cell apoptosis, and enzymatic reactions in which the GET1/2 complex is indispensable. However, a comprehensive study of the GET1 and GET2 genes and the GET pathway in cotton has not yet been carried out. Here, 12 GET1 and 21 GET2 genes were identified in nine representative plant species, and the phylogenetic relationships, gene structures, protein motifs, cis-regulatory elements (CREs), and temporal and spatial expression profiles were analyzed thoroughly. Our study indicated that GhGET1s and GhGET2s might be localized on ER membranes. According to expression profiling and CREs analysis, GhGET2-A02 was identified as a promising candidate for fiber cell development, interacting with two GhGET1s in the membrane, with a binding bias toward GhGET1-A06. Silencing of GhGET1-A06 or GhGET2-A02 reduced fiber initiation and elongation. In summary, our research provides important evidence for understanding the gene families and functions of GET1 and GET2 in cotton and provides clues for molecular breeding of high-quality cotton fiber varieties.

01 Sep 2024·PROTEOMICS

Proteome‐wide abundance profiling of yeast deletion strains for GET pathway members using sample multiplexing

Article

Author: Levi, Benjamin P. ; Paulo, Joao A. ; Gygi, Joel S. ; Liu, Xinyue.

AbstractThe GET pathway is associated with post‐translational delivery of tail‐anchored (TA) proteins to the endoplasmic reticulum (ER) in yeast, as well as other eukaryotes. Moreover, dysfunction of the GET pathway has been associated with various pathological conditions (i.e., neurodegenerative disorders, cardiovascular ailments, and protein misfolding diseases). In this study, we used yeast deletion strains of Get complex members (specifically, Get1, Get2, Get3, Get4, and Get5) coupled with sample multiplexing‐based quantitative mass spectrometry to profile protein abundance on a proteome‐wide scale across the five individual deletion strains. Our dataset consists of over 4500 proteins, which corresponds to >75% of the yeast proteome. The data reveal several dozen proteins that are differentially abundant in one or more deletion strains, some of which are membrane‐associated, yet the abundance of many TA proteins remained unchanged. This study provides valuable insights into the roles of these Get genes, and the potential for alternative pathways which help maintain cellular function despite the disruption of the GET pathway.

News (Medical) associated with CAMLG

31 Jul 2024

·www.prnewswire.com

CREATV BIO ANNOUNCES ITS CAML BIOMARKER INCLUDED IN PIVOTAL PHASE 3 TRIAL IN METASTATIC BREAST CANCER

MONMOUTH JUNCTION, N.J., July 31, 2024 /PRNewswire/ -- Creatv Bio, a Division of Creatv MicroTech, Inc. (Creatv) announced that its Cancer Associated Macrophage-Like (CAML) liquid biopsy biomarker has been included as part of the pivotal Phase 3 trial of BriaCell Therapeutics Corporation's lead clinical candidate, Bria-IMT in combination with an immune checkpoint inhibitor in metastatic breast cancer. This study is expected to enroll a total of 404 patients in two arms – Bria-IMT in combination with an immune checkpoint inhibitor versus treatment of physicians' choice in late-stage metastatic breast cancer patients, with no approved alternative therapies available (listed on ClinicalTrials.gov as NCT06072612). Bria-IMT was awarded Fast Track status by the U.S. Food and Drug Administration (FDA). Blood samples are being provided to Creatv to analyze for the presence of circulating tumor cells (CTCs), CAML subtyping, and to monitor PD-L1 upregulation in patients. The samples are being taken at baseline and at a designated time following the initial patient treatment. Creatv previously demonstrated that CAMLs can accurately (i) predict a cancer's aggressiveness as well as multi-organ metastasis, (ii) provide a universal companion diagnostics tool using blood instead of tissue from patients, (iii) predict treatment response within approximately 30 days of receiving a new therapy in any solid tumor type, (iv) detect minimal residual disease, and (v) cancer recurrence. "The use of biomarkers like CAMLs holds great promise in helping clinicians determine whether a patient is responding to a specific therapy in a timely manner," remarked Dr. Cha-Mei Tang, President and CEO of Creatv Bio. "We are looking forward to participating in this important trial with BriaCell and are confident that as a result, this biomarker will provide clinicians with a valuable tool to guide their treatment choices for cancer patients." About Creatv Bio Creatv is a cancer screening and cancer diagnostics company providing testing services to patients and to support drug development from its CLIA/CAP laboratory in NJ. Creatv's scientists were the first to publish CAMLs found in the blood of cancer patients. Since this original publication in 2014, CAMLs have been validated by dozens of independent groups worldwide. For a complete listing of our journal publications and posters, please visit our website at . For more information contact: SOURCE Creatv MicroTech, Inc.

Phase 3ImmunotherapyFast Track

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

CAMLG

Basic Info

Related

Analysis